Aim To determine pre- and post-dosi

Aim To determine pre- and post-dosing effects of prenatal methadone compared to buprenorphine on fetal wellbeing.
Design A secondary analysis of data derived from the Maternal Opioid Treatment: Human Experimental Research
(MOTHER) study, a double-blind, double-dummy, randomized clinical trial. Setting Six United States sites
and one European site that provided comprehensive opioid-dependence treatment to pregnant women.
Participants Eighty-one of the 131 opioid-dependent pregnant women completing the MOTHER clinical trial,
assessed between 31 and 33 weeks of gestation. Measurements Two fetal assessments were conducted, once before
and once after study medication dosing. Measures included mean fetal heart rate (FHR), number of FHR accelerations,
FHR reactivity in the fetal non-stress test (NST) and biophysical profile (BPP) score. Findings Significant group
differences were found for number of FHR accelerations, non-reactive NST and BPP scores (all Ps < 0.05). There were
no significant group differences before time of dosing. Significant decreases (all Ps < 0.05) occurred from pre- to
post-dose assessment for mean FHR, FHR accelerations, reactive NST and fetal movement. The decrease in accelerations
and reactive NST were significant only for fetuses in the methadone group, and this resulted in a significantly
lower likelihood of a reactive NST compared to fetuses in the buprenorphine group. Conclusion Buprenorphine
compared with methadone appears to result in less suppression of mean fetal heart rate, fetal heart rate reactivity and
the biophysical profile score after medication dosing and these findings provide support for the relative safety of
buprenorphine when fetal indices are considered as part of the complete risk–benefit ratio.

ผลลัพธ์ (อังกฤษ) 2:

Aim To Determine Post-dosing and pre-Prenatal effects of methadone compared to buprenorphine on fetal Wellbeing.
Design A Secondary Analysis of Data derived from the Maternal Opioid Treatment: Human Experimental Research
(MOTHER) Study, a double-blind, double-dummy,. randomized clinical trial. Setting Six United States sites
and one European Site that provided opioid-dependence Comprehensive Treatment to pregnant Women.
Participants Eighty-one of the 131 opioid-dependent pregnant Women MOTHER completing the clinical Trial,
between 31 and 33 weeks of gestation Assessed. Two measurements were conducted fetal Assessments, once before
and once after Study Medication dosing. Mean measures included fetal Heart rate (FHR), Number of FHR accelerations,
FHR reactivity in the fetal non-Stress Test (NST) and biophysical Profile (BPP) Score. Group Findings Significant
differences were Found for Number of FHR accelerations, non-reactive NST and BPP Scores (all Ps <.05). There were
no significant differences before time Group of dosing. Significant decreases (all Ps <0:05) occurred from pre-to
-Post Assessment for dose Mean FHR, FHR accelerations, reactive NST and fetal Movement. The decrease in accelerations
and reactive NST were significant only for fetuses in the methadone Group, and this resulted in a significantly
Lower likelihood of a reactive NST compared to fetuses in the buprenorphine Group. Conclusion Buprenorphine
compared with methadone appears to Result in Less suppression of Mean fetal Heart rate, fetal Heart rate reactivity and
the biophysical Profile Score after Medication dosing and these findings provide Support for the Relative safety of
buprenorphine when fetal indices are considered as Part of the Complete. risk-benefit ratio.

ผลลัพธ์ (อังกฤษ) 3:

Aim To determine pre - and post-dosing effects of prenatal methadone compared to buprenorphine on fetal wellbeing.Design A secondary analysis of data derived from the Maternal Opioid Treatment: Human Experimental Research.(MOTHER), study a double - blind double-dummy randomized,, clinical trial. Setting Six United States sites.And one European site that provided comprehensive opioid-dependence treatment to pregnant women.Participants Eighty-one of the 131 opioid-dependent pregnant women completing the MOTHER, clinical trialAssessed between 31 and 33 weeks of gestation. Measurements Two fetal assessments were conducted once before,,And once after study medication dosing. Measures included mean fetal heart rate (FHR), number of, FHR accelerationsFHR reactivity in the fetal non-stress test (NST) and biophysical profile (BPP) score. Findings Significant group.Differences were found for number of FHR accelerations non-reactive NST, and BPP scores (all Ps < 0.05). There were.No significant group differences before time of dosing. Significant decreases (all Ps < 0.05) occurred from pre - to.Post-dose assessment for FHR mean, accelerations FHR, NST reactive and fetal movement. The decrease in accelerations.And reactive NST were significant only for fetuses in the, methadone group and this resulted in a significantly.Lower likelihood of a reactive NST compared to fetuses in the buprenorphine group. Conclusion Buprenorphine.Compared with methadone appears to result in less suppression of mean fetal, heart rate fetal heart rate reactivity and.The biophysical profile score after medication dosing and these findings provide support for the relative safety of.Buprenorphine when fetal indices are considered as part of the complete risk - benefit ratio.